

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

JUL 1 2004 8:09AM

GLAXO WELLCOME

NO. 4208 P. 1



GlaxoSmithKline

Glaxo Wellcome Inc.  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
www.gsk.com

To Box Issue Fee

Company USPTO

Fax 703-746-4000

From Allyson K. Jacobs

Tel 919-483-9105 Fax 919-483-7988

E-mail [aki27836@gsk.com](mailto:aki27836@gsk.com)

Date July 1, 2004 Pages Including cover 11

Subject Serial No.: 10/669,400;

Filing Date: 9/23/03

Attached:

Amendment Under 37 C.F.R. 1.312  
Information Disclosure Statement + copy  
PTO 1449  
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.